Advertisement
Screener

GALECTIN THERAPEUTICS INC. (GALT) Research and Development Expense

2.8 / 5 stars · 68/120 Roast Me

GALECTIN THERAPEUTICS INC. Research and Development Expense

GALECTIN THERAPEUTICS INC. (GALT) reported Research and Development Expense of $2.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14

  • GALECTIN THERAPEUTICS INC. research and development expense for the quarter ending 2026-06-30 was $2.13M, a 34.53% decline year-over-year.
  • GALECTIN THERAPEUTICS INC. research and development expense for the quarter ending 2026-03-31 was $2.23M, a 65.60% decline year-over-year.
  • GALECTIN THERAPEUTICS INC. research and development expense for the quarter ending 2025-12-31 was $1.93M, a 82.60% decline year-over-year.
  • GALECTIN THERAPEUTICS INC. research and development expense for the quarter ending 2025-09-30 was $2.61M, a 65.62% decline year-over-year.
  • GALECTIN THERAPEUTICS INC. research and development expense for fiscal 2025 was $14.29M, a 60.93% decline from fiscal 2024.
  • GALECTIN THERAPEUTICS INC. research and development expense for fiscal 2024 was $36.57M, a 13.82% increase from fiscal 2023.
  • GALECTIN THERAPEUTICS INC. research and development expense for fiscal 2023 was $32.13M, a 1.24% increase from fiscal 2022.
  • GALECTIN THERAPEUTICS INC. research and development expense for fiscal 2022 was $31.74M, a 33.25% increase from fiscal 2021.
Period endResearch and Development Expense 3 monthResearch and Development Expense 6 monthResearch and Development Expense 9 monthResearch and Development Expense 12 monthResearch and Development Expense 132 monthResearch and Development Expense 135 monthResearch and Development Expense 138 monthResearch and Development Expense 141 monthResearch and Development Expense 144 monthResearch and Development Expense 147 monthResearch and Development Expense 150 monthResearch and Development Expense 153 monthResearch and Development Expense 156 monthResearch and Development Expense 159 monthResearch and Development Expense 162 monthResearch and Development Expense 165 month
2026-06-30$2.13M
10-Q · filed 2026-08-14
$4.37M
10-Q · filed 2026-08-14
$6.30M
derived: sum of 3 quarters · filed 2026-08-14
$8.91M
derived: sum of 4 quarters · filed 2026-08-14
2026-03-31$2.23M
10-Q · filed 2026-05-15
$4.16M
derived: sum of 2 quarters · filed 2026-05-15
$6.78M
derived: sum of 3 quarters · filed 2026-05-15
$10.04M
derived: sum of 4 quarters · filed 2026-08-14
2025-12-31$1.93M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31
$4.54M
derived: sum of 2 quarters · filed 2026-03-31
$7.80M
derived: sum of 3 quarters · filed 2026-08-14
$14.29M
10-K · filed 2026-03-31
2025-09-30$2.61M
10-Q · filed 2025-11-14
$5.87M
derived: sum of 2 quarters · filed 2026-08-14
$12.36M
10-Q · filed 2025-11-14
$23.47M
derived: sum of 4 quarters · filed 2026-08-14
2025-06-30$3.26M
10-Q · filed 2026-08-14
$9.75M
10-Q · filed 2026-08-14
$20.86M
derived: sum of 3 quarters · filed 2026-08-14
$28.45M
derived: sum of 4 quarters · filed 2026-08-14
2025-03-31$6.49M
10-Q · filed 2026-05-15
$17.59M
derived: sum of 2 quarters · filed 2026-05-15
$25.19M
derived: sum of 3 quarters · filed 2026-05-15
$35.00M
derived: sum of 4 quarters · filed 2026-05-15
2024-12-31$11.11M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31
$18.70M
derived: sum of 2 quarters · filed 2026-03-31
$28.52M
derived: sum of 3 quarters · filed 2026-03-31
$36.57M
10-K · filed 2026-03-31
2024-09-30$7.59M
10-Q · filed 2025-11-14
$17.41M
derived: sum of 2 quarters · filed 2025-11-14
$25.46M
10-Q · filed 2025-11-14
$33.69M
derived: sum of 4 quarters · filed 2025-11-14
2024-06-30$9.81M
10-Q · filed 2025-08-14
$17.87M
10-Q · filed 2025-08-14
$26.09M
derived: sum of 3 quarters · filed 2025-08-14
$33.83M
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31$8.05M
10-Q · filed 2025-05-15
$16.28M
derived: sum of 2 quarters · filed 2025-05-15
$24.01M
derived: sum of 3 quarters · filed 2025-05-15
$31.39M
derived: sum of 4 quarters · filed 2025-05-15
2023-12-31$8.23M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31
$15.96M
derived: sum of 2 quarters · filed 2025-03-31
$23.33M
derived: sum of 3 quarters · filed 2025-03-31
$32.13M
10-K · filed 2025-03-31
2023-09-30$7.73M
10-Q · filed 2024-11-14
$15.10M
derived: sum of 2 quarters · filed 2024-11-14
$23.90M
10-Q · filed 2024-11-14
$32.91M
derived: sum of 4 quarters · filed 2024-11-14
2023-06-30$7.37M
10-Q · filed 2024-08-13
$16.17M
10-Q · filed 2024-08-13
$25.18M
derived: sum of 3 quarters · filed 2024-08-13
$31.77M
derived: sum of 4 quarters · filed 2024-08-13
2023-03-31$8.80M
10-Q · filed 2024-05-15
$17.81M
derived: sum of 2 quarters · filed 2024-05-15
$24.40M
derived: sum of 3 quarters · filed 2024-05-15
$32.48M
derived: sum of 4 quarters · filed 2024-05-15
2022-12-31$9.01M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29
$15.61M
derived: sum of 2 quarters · filed 2024-03-29
$23.68M
derived: sum of 3 quarters · filed 2024-03-29
$31.74M
10-K · filed 2024-03-29
2022-09-30$6.60M
10-Q · filed 2023-11-13
$14.67M
derived: sum of 2 quarters · filed 2023-11-13
$22.73M
10-Q · filed 2023-11-13
$28.59M
derived: sum of 4 quarters · filed 2023-11-13
2022-06-30$8.07M
10-Q · filed 2023-08-14
$16.13M
10-Q · filed 2023-08-14
$21.99M
derived: sum of 3 quarters · filed 2023-08-14
$28.60M
derived: sum of 4 quarters · filed 2023-08-14
2022-03-31$8.06M
10-Q · filed 2023-05-15
$13.91M
derived: sum of 2 quarters · filed 2023-05-15
$20.53M
derived: sum of 3 quarters · filed 2023-05-15
$26.98M
derived: sum of 4 quarters · filed 2023-05-15
2021-12-31$5.86M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30
$12.47M
derived: sum of 2 quarters · filed 2023-03-30
$18.92M
derived: sum of 3 quarters · filed 2023-03-30
$23.82M
10-K · filed 2023-03-30
2021-09-30$6.61M
10-Q · filed 2022-11-14
$13.06M
derived: sum of 2 quarters · filed 2022-11-14
$17.96M
10-Q · filed 2022-11-14
$24.33M
derived: sum of 4 quarters · filed 2022-11-14
2021-06-30$6.45M
10-Q · filed 2022-08-15
$11.35M
10-Q · filed 2022-08-15
$17.72M
derived: sum of 3 quarters · filed 2022-08-15
$22.50M
derived: sum of 4 quarters · filed 2022-08-15
2021-03-31$4.90M
10-Q · filed 2022-05-16
$11.27M
derived: sum of 2 quarters · filed 2022-05-16
$16.05M
derived: sum of 3 quarters · filed 2022-05-16
$20.73M
derived: sum of 4 quarters · filed 2022-05-16
2020-12-31$6.37M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31
$11.15M
derived: sum of 2 quarters · filed 2022-03-31
$15.83M
derived: sum of 3 quarters · filed 2022-03-31
$17.98M
10-K · filed 2022-03-31
2020-09-30$4.78M
10-Q · filed 2021-11-15
$9.46M
derived: sum of 2 quarters · filed 2021-11-15
$11.61M
10-Q · filed 2021-11-15
$15.40M
derived: sum of 4 quarters · filed 2021-11-15
2020-06-30$4.68M
10-Q · filed 2021-08-16
$6.83M
10-Q · filed 2021-08-16
$10.62M
derived: sum of 3 quarters · filed 2021-08-16
$12.12M
derived: sum of 4 quarters · filed 2021-08-16
2020-03-31$2.14M
10-Q · filed 2021-05-17
$5.94M
derived: sum of 2 quarters · filed 2021-05-17
$7.44M
derived: sum of 3 quarters · filed 2021-05-17
$8.96M
derived: sum of 4 quarters · filed 2021-05-17
2019-12-31$3.80M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31
$5.30M
derived: sum of 2 quarters · filed 2021-03-31
$6.82M
derived: sum of 3 quarters · filed 2021-03-31
$7.47M
10-K · filed 2021-03-31
2019-09-30$1.50M
10-Q · filed 2020-11-09
$3.02M
derived: sum of 2 quarters · filed 2020-11-09
$3.67M
10-Q · filed 2020-11-09
$4.86M
derived: sum of 4 quarters · filed 2020-11-09
2019-06-30$1.52M
10-Q · filed 2020-08-10
$2.17M
10-Q · filed 2020-08-10
$3.36M
derived: sum of 3 quarters · filed 2020-08-10
$4.87M
derived: sum of 4 quarters · filed 2020-08-10
2019-03-31$646.00K
10-Q · filed 2020-05-11
$1.84M
derived: sum of 2 quarters · filed 2020-05-11
$3.34M
derived: sum of 3 quarters · filed 2020-05-11
$4.82M
derived: sum of 4 quarters · filed 2020-05-11
2018-12-31$1.19M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16
$2.70M
derived: sum of 2 quarters · filed 2020-03-16
$4.17M
derived: sum of 3 quarters · filed 2020-03-16
$6.47M
10-K · filed 2020-03-16
2018-09-30$1.50M
10-Q · filed 2019-11-12
$2.98M
derived: sum of 2 quarters · filed 2019-11-12
$5.28M
10-Q · filed 2019-11-12
$6.28M
derived: sum of 4 quarters · filed 2019-11-12
2018-06-30$1.48M
10-Q · filed 2019-08-09
$3.77M
10-Q · filed 2019-08-09
$4.78M
derived: sum of 3 quarters · filed 2019-08-09
$8.28M
derived: sum of 4 quarters · filed 2019-08-09
2018-03-31$2.30M
10-Q · filed 2019-05-10
$3.30M
derived: sum of 2 quarters · filed 2019-05-10
$6.80M
derived: sum of 3 quarters · filed 2019-05-10
$10.25M
derived: sum of 4 quarters · filed 2019-05-10
2017-12-31$1.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06
$4.50M
derived: sum of 2 quarters · filed 2019-03-06
$7.95M
derived: sum of 3 quarters · filed 2019-03-06
$11.72M
10-K · filed 2019-03-06
2017-09-30$3.50M
10-Q · filed 2018-11-13
$6.95M
derived: sum of 2 quarters · filed 2018-11-13
$10.72M
10-Q · filed 2018-11-13
$14.15M
derived: sum of 4 quarters · filed 2018-11-13
2017-06-30$3.44M
10-Q · filed 2018-08-14
$7.22M
10-Q · filed 2018-08-14
$10.65M
derived: sum of 3 quarters · filed 2018-08-14
$13.94M
derived: sum of 4 quarters · filed 2018-08-14
2017-03-31$3.77M
10-Q · filed 2018-05-11
$7.21M
derived: sum of 2 quarters · filed 2018-05-11
$10.49M
derived: sum of 3 quarters · filed 2018-05-11
$14.72M
derived: sum of 4 quarters · filed 2018-05-11
2016-12-31$3.43M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29
$6.72M
derived: sum of 2 quarters · filed 2018-03-29
$10.95M
derived: sum of 3 quarters · filed 2018-03-29
$15.32M
10-K · filed 2018-03-29
2016-09-30$3.29M
10-Q · filed 2017-11-07
$7.51M
derived: sum of 2 quarters · filed 2017-11-07
$11.89M
10-Q · filed 2017-11-07
$14.81M
derived: sum of 4 quarters · filed 2017-11-07
2016-06-30$4.23M
10-Q · filed 2017-08-14
$8.60M
10-Q · filed 2017-08-14
$11.52M
derived: sum of 3 quarters · filed 2017-08-14
$15.98M
derived: sum of 4 quarters · filed 2017-08-14
2016-03-31$4.38M
10-Q · filed 2017-05-15
$7.29M
derived: sum of 2 quarters · filed 2017-05-15
$11.76M
derived: sum of 3 quarters · filed 2017-05-15
$14.36M
derived: sum of 4 quarters · filed 2017-05-15
2015-12-31$2.91M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-28
$7.38M
derived: sum of 2 quarters · filed 2017-03-28
$9.98M
derived: sum of 3 quarters · filed 2017-03-28
$13.11M
10-K · filed 2017-03-28
2015-09-30$4.46M
10-Q · filed 2016-11-08
$7.06M
derived: sum of 2 quarters · filed 2016-11-08
$10.20M
10-Q · filed 2016-11-08
$12.28M
derived: sum of 4 quarters · filed 2016-11-08
2015-06-30$2.60M
10-Q · filed 2016-08-09
$5.74M
10-Q · filed 2016-08-09
$7.82M
derived: sum of 3 quarters · filed 2016-08-09
$9.79M
derived: sum of 4 quarters · filed 2016-08-09
2015-03-31$3.14M
10-Q · filed 2016-05-10
$5.22M
derived: sum of 2 quarters · filed 2016-05-10
$7.20M
derived: sum of 3 quarters · filed 2016-05-10
$8.79M
derived: sum of 4 quarters · filed 2016-05-10
2014-12-31$2.08M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15
$4.06M
derived: sum of 2 quarters · filed 2016-03-15
$5.65M
derived: sum of 3 quarters · filed 2016-03-15
$8.43M
10-K · filed 2016-03-15
2014-09-30$1.98M
10-Q · filed 2015-11-09
$3.57M
derived: sum of 2 quarters · filed 2015-11-09
$6.34M
10-Q · filed 2015-11-09
$7.74M
derived: sum of 4 quarters · filed 2016-03-15
2014-06-30$1.59M
10-Q · filed 2015-08-10
$4.37M
10-Q · filed 2015-08-10
$5.76M
derived: sum of 3 quarters · filed 2016-03-15
$6.95M
derived: sum of 4 quarters · filed 2016-03-15
2014-03-31$2.77M
10-Q · filed 2015-05-11
$4.17M
derived: sum of 2 quarters · filed 2016-03-15
$5.36M
derived: sum of 3 quarters · filed 2016-03-15
$6.71M
derived: sum of 4 quarters · filed 2016-03-15
$36.07M
10-Q · filed 2014-05-13
2013-12-31$1.40M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15
$2.59M
derived: sum of 2 quarters · filed 2016-03-15
$3.94M
derived: sum of 3 quarters · filed 2016-03-15
$5.69M
10-K · filed 2016-03-15
$33.30M
10-K · filed 2014-03-21
2013-09-30$1.19M
10-Q · filed 2014-11-10
$2.54M
derived: sum of 2 quarters · filed 2014-11-10
$4.29M
10-Q · filed 2014-11-10
$5.29M
derived: sum of 4 quarters · filed 2015-03-18
$31.90M
10-Q · filed 2013-11-12
2013-06-30$1.35M
10-Q · filed 2013-08-14
$3.10M
10-Q · filed 2014-08-07
$4.10M
derived: sum of 3 quarters · filed 2015-03-18
$5.51M
derived: sum of 4 quarters · filed 2015-03-18
$30.71M
10-Q · filed 2013-08-14
2013-03-31$1.75M
10-Q · filed 2014-05-13
$2.75M
derived: sum of 2 quarters · filed 2015-03-18
$4.16M
derived: sum of 3 quarters · filed 2015-03-18
$5.38M
derived: sum of 4 quarters · filed 2015-03-18
$29.36M
10-Q · filed 2013-05-10
2012-12-31$1.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-18
$2.41M
derived: sum of 2 quarters · filed 2015-03-18
$3.63M
derived: sum of 3 quarters · filed 2015-03-18
$4.53M
10-K · filed 2015-03-18
$27.61M
10-K · filed 2013-03-29
2012-09-30$1.41M
10-Q · filed 2013-11-12
$2.62M
derived: sum of 2 quarters · filed 2013-11-12
$3.52M
10-Q · filed 2013-11-12
$4.39M
derived: sum of 4 quarters · filed 2013-11-12
$26.61M
10-Q · filed 2012-11-09
2012-06-30$1.22M
10-Q · filed 2013-08-14
$2.12M
10-Q · filed 2013-08-14
$2.98M
derived: sum of 3 quarters · filed 2013-08-14
$3.63M
derived: sum of 4 quarters · filed 2013-08-14
$25.20M
10-Q · filed 2012-08-10
2012-03-31$901.00K
10-Q · filed 2013-05-10
$1.76M
derived: sum of 2 quarters · filed 2013-05-10
$2.42M
derived: sum of 3 quarters · filed 2013-05-10
$3.71M
derived: sum of 4 quarters · filed 2013-05-10
$23.98M
10-Q · filed 2012-05-11
2011-12-31$862.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-29
$1.52M
derived: sum of 2 quarters · filed 2013-03-29
$2.81M
derived: sum of 3 quarters · filed 2013-03-29
$3.55M
10-K · filed 2013-03-29
$23.08M
10-K · filed 2012-03-30
2011-09-30$655.00K
10-Q · filed 2012-11-09
$1.95M
derived: sum of 2 quarters · filed 2012-11-09
$2.69M
10-Q · filed 2012-11-09
$3.08M
derived: sum of 4 quarters · filed 2012-11-09
$22.22M
10-Q · filed 2011-11-10
2011-06-30$1.29M
10-Q · filed 2012-08-10
$2.04M
10-Q · filed 2012-08-10
$2.42M
derived: sum of 3 quarters · filed 2012-08-10
$2.74M
derived: sum of 4 quarters · filed 2012-08-10
$21.57M
10-Q · filed 2011-08-12
2011-03-31$744.00K
10-Q · filed 2012-05-11
$1.13M
derived: sum of 2 quarters · filed 2012-05-11
$1.45M
derived: sum of 3 quarters · filed 2012-05-11
$1.68M
derived: sum of 4 quarters · filed 2012-05-11
2010-12-31$390.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-30
$703.00K
derived: sum of 2 quarters · filed 2012-03-30
$937.00K
derived: sum of 3 quarters · filed 2012-03-30
$1.07M
10-K · filed 2012-03-30
2010-09-30$313.00K
10-Q · filed 2011-11-10
$547.00K
derived: sum of 2 quarters · filed 2011-11-10
$676.00K
10-Q · filed 2011-11-10
2010-06-30$234.00K
10-Q · filed 2011-08-12
$363.00K
10-Q · filed 2011-08-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Arcturus Therapeutics Holdings Inc. (ARCT)$0.402B-2.05
Turn Therapeutics Inc. (TTRX)United States$0.397B-25.68
Opus Genetics, Inc. (IRD)United States$0.406B-3.16
RELMADA THERAPEUTICS, INC. (RLMD)United States$0.406B-11.92
ARS Pharmaceuticals, Inc. (SPRY)United States$0.414B-3.70
Atea Pharmaceuticals, Inc. (AVIR)United States$0.414B-2.26
Rezolute, Inc. (RZLT)United States$0.382B-6.45
DiaMedica Therapeutics Inc. (DMAC)United States$0.423B-10.11
PROTHENA CORP PUBLIC LTD CO (PRTA)Ireland$0.428B-11.53
CYPHERPUNK TECHNOLOGIES INC. (CYPH)United States$0.438B-75.63